.Pharmacolibrary.Drugs.N_NervousSystem.N06D_AntiDementiaDrugs.N06DX01_Memantine.Memantine

Information

Memantine is a moderate-affinity, uncompetitive NMDA receptor antagonist used primarily in the management of moderate to severe Alzheimer's disease. Memantine is approved and widely used for symptomatic treatment to slow cognitive decline in neurodegenerative conditions.

Pharmacokinetics

Pharmacokinetic parameters reported from healthy adult volunteers after a single oral administration.

References

1. Kornhuber, J, et al., & Meineke, I (2007). Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clinical pharmacokinetics 46(7) 599–612. DOI:10.2165/00003088-200746070-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17596105

2. Moritoyo, T, et al., & Nomoto, M (2012). Effect of renal impairment on the pharmacokinetics of memantine. Journal of pharmacological sciences 119(4) 324–329. DOI:10.1254/jphs.12043fp PUBMED:https://pubmed.ncbi.nlm.nih.gov/22863669

3. Glass, OM, et al., & Schwartz, AC (2020). Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service. Current psychiatry reports 22(5) 21–None. DOI:10.1007/s11920-020-01147-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32285305

Revisions

• 06/2025 initial generated model